This has been productively investigated in CD8+ T cells, where exhaustion is characterized by the expression of negative regulatory coreceptors, such as CTLA4, PD-1 and Tim-3, and blockade of these receptors with checkpoint inhibitors to restore CD8+ T-cell immunity has revolutionised the treatment of some forms of cancer [1–3]. The gene discussed is CD8A; the disease is cancer.